Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Bayer Aktienges Ads (BAYRY)

Bayer Aktienges Ads (BAYRY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 78,091,824
  • Shares Outstanding, K 3,730,204
  • Annual Sales, $ 46,751 M
  • Annual Income, $ 2,002 M
  • 60-Month Beta 1.03
  • Price/Sales 1.52
  • Price/Cash Flow 5.55
  • Price/Book 1.53
  • Price/Earnings ttm 11.59
  • Earnings Per Share ttm 1.81
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/26/20
  • Annual Dividend & Yield 0.55 (2.61%)
  • Most Recent Dividend 0.546 on 04/29/19
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.34
  • Number of Estimates 1
  • High Estimate 0.34
  • Low Estimate 0.34
  • Prior Year 0.31
  • Growth Rate Est. (year over year) +9.68%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.6300 +6.65%
on 12/20/19
21.1000 -0.78%
on 01/15/20
+1.3360 (+6.82%)
since 12/17/19
3-Month
17.9500 +16.63%
on 10/22/19
21.1000 -0.78%
on 01/15/20
+2.6550 (+14.52%)
since 10/17/19
52-Week
14.6100 +43.29%
on 05/31/19
21.1000 -0.78%
on 01/15/20
+2.5050 (+13.59%)
since 01/17/19

Most Recent Stories

More News
Serine Threonine Protein Kinase ATR, Pipeline Review, H2 2019 - Artios Pharma Ltd, Bayer AG, IMPACT Therapeutics Inc & Pfizer Inc - ResearchAndMarkets.com

The "Serine Threonine Protein Kinase ATR - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

BAYRY : 20.9350 (-0.21%)
PFE : 40.51 (-0.25%)
Colorectal Cancer Therapeutics Market to reach USD 16.58 billion by 2026, Presence of Strong Oncology Portfolio to help Players Gain Competitive: Reports Fortune Business Insights(TM)

The global Colorectal Cancer Therapeutics Market size is projected to reach USD 16.58 billion by 2026, owing to the rise in the prevalence of colorectal cancer worldwide. A report by Fortune Business Insights(TM)...

BAYRY : 20.9350 (-0.21%)
LLY : 139.58 (-1.31%)
MRK : 90.97 (-0.23%)
PFE : 40.51 (-0.25%)
REGN : 385.94 (+0.10%)
TEVA : 10.20 (-3.95%)
Seeds Market in US 2019-2023| Evolving Opportunities with BASF SE and Bayer AG | Technavio

The seeds market in the US is poised to grow by USD 12.28 billion during 2019-2023, progressing at a CAGR of almost 9% during the forecast period. Request Free Sample Pages

BAYRY : 20.9350 (-0.21%)
Ultragenyx's Gene Therapy Positive in Genetic Disorder Study

Shares of Ultragenyx (RARE) rise 23.4% after releasing positive top-line data from the phase I/II study of its gene therapy candidate DTX301 for the treatment of OTC deficiency.

BAYRY : 20.9350 (-0.21%)
ALXN : 113.27 (+0.68%)
RARE : 59.96 (-1.51%)
CUE : 15.40 (-8.17%)
Elanco Signs Agreement with PetIQ to Divest Capstar(R)

Elanco Animal Health Incorporated (NYSE: ELAN) announced today it signed an agreement to divest the U.S. rights to Capstar(R), an oral tablet that kills fleas in dogs and cats, to PetIQ, Inc. (Nasdaq:...

BAYRY : 20.9350 (-0.21%)
PETQ : 30.74 (-1.66%)
BAYN : 0.0147 (unch)
ELAN : 30.00 (-1.99%)
Bayer AG and Monsanto Look to Minimize Losses from Cancer Victims' Exposure to Roundup

Bayer AG (OTCMKTS: BAYZF) and its Monsanto subsidiary are hoping to minimize losses at the expense of nearly 43,000 cancer victims who have filed suit after falling ill following exposure to the popular...

BAYRY : 20.9350 (-0.21%)
BAYZF : 82.4000 (-1.55%)
Bayer AG and Monsanto Look to Minimize Losses from Cancer Victims' Exposure to Roundup

DALLAS , Jan. 11, 2020 /PRNewswire/ -- Bayer AG (OTCMKTS: BAYZF) and its Monsanto subsidiary are hoping to minimize losses at the expense of nearly 43,000 cancer victims who have filed suit after...

BAYZF : 82.4000 (-1.55%)
BAYRY : 20.9350 (-0.21%)
Regeneron's Phase II Candidate Promising in Primary Analysis

Regeneron (REGN) announces encouraging results from the phase II study on rare bone disease candidate.

NVS : 95.93 (+0.87%)
SNY : 51.24 (+0.10%)
BAYRY : 20.9350 (-0.21%)
REGN : 385.94 (+0.10%)
Blueprint Medicines' Ayvakit Gets FDA Nod for Rare Cancer

Blueprint Medicines (BPMC) gets its maiden FDA approval for its lead candidate Ayvakit to treat adult patients with PDGFRA Exon 18 mutant gastrointestinal stromal tumor (GIST).

BAYRY : 20.9350 (-0.21%)
RHHBY : 42.4200 (+1.60%)
EBS : 55.56 (-0.86%)
BPMC : 81.10 (+0.17%)
Exelixis to Expand Prostate Cancer Cohort of Cabometyx Study

Exelixis (EXEL) plans to further expand the metastatic CRPC cohort of the phase Ib study on lead drug, Cabometyx.

MRK : 90.97 (-0.23%)
RHHBY : 42.4200 (+1.60%)
BAYRY : 20.9350 (-0.21%)
EXEL : 19.82 (-3.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade BAYRY with:

Key Turning Points

2nd Resistance Point 21.1157
1st Resistance Point 21.0253
Last Price 20.9350
1st Support Level 20.8533
2nd Support Level 20.7717

See More

52-Week High 21.1000
Last Price 20.9350
Fibonacci 61.8% 18.6208
Fibonacci 50% 17.8550
Fibonacci 38.2% 17.0892
52-Week Low 14.6100

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar